NuGen Medical Devices Inc.
NGMDF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.01 | 0.01 | -0.07 |
| FCF Yield | -8.96% | -6.18% | -8.38% | -17.60% |
| EV / EBITDA | -29.56 | -17.13 | 8.09 | 19.40 |
| Quality | ||||
| ROIC | -12.34% | -9.24% | -7.23% | -7.21% |
| Gross Margin | 60.92% | 60.17% | 55.26% | 54.11% |
| Cash Conversion Ratio | 0.56 | 0.31 | -0.52 | -5.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 66.50% | 308.69% | 114.66% | 87.85% |
| Free Cash Flow Growth | -48.06% | 6.90% | 70.76% | -213.64% |
| Safety | ||||
| Net Debt / EBITDA | -15.56 | -8.45 | 4.02 | 7.87 |
| Interest Coverage | -1.49 | -1.35 | -1.25 | -1.21 |
| Efficiency | ||||
| Inventory Turnover | 0.04 | 0.03 | 0.13 | 0.59 |
| Cash Conversion Cycle | -107.33 | -810.93 | 110.46 | -91.45 |